Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplantation
NCT03739502Phase 2Active, not recruiting
- Sponsor
- University of Rochester
- Start
- Feb 2019
- Primary completion
- Jun 2027
- Modality
- NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hyperbaric oxygen therapy in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and 2 more (2 arms), sponsored by University of Rochester. Primary endpoint: Time to neutrophil recovery at 100 days. Started Feb 2019; status: active, not recruiting.
02
Drugs
hyperbaric oxygen therapy
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03739502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739502.